HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Traditional Chinese Medicine

670.499

-0.815-0.12%

Number of Gainers:5

Number of Losers:5

Number of Flat:1

PE:- -

High:682.666

Open:674.697

Low:665.867

Close:671.314

Volume:100.48M

Turnover:241.05M

Market Cap:70.73B

Float Cap:47.38B

Loading ...

BAIYUNSHAN PH Reports Interim Results with Net Profit Attributable to Shareholders of Approximately RMB 2.096 Billion, Down 16.7% Year-on-Year

Modern Chinese Medicine Group Flags Expected Interim Loss of Approximately RMB 25.9 Million

Modern Chinese Medicine Expects RMB 25.9 Million H1 Net Loss vs RMB 2.5 Million Profit a Year Earlier

Modern Chinese Medicine Group Co - Expects Net Loss of Rmb25.9 Mln for Six Months Ended June 2026

THOMSON REUTERS

Modern Chinese Medicine Group Co - Hy Net Loss Mainly Due to Increased Promotion, Marketing, Research and Development Expenses

THOMSON REUTERS

Luye Pharma's Vaccine for Cervical Precancerous Lesions to Enter Phase II Trial

MT Newswires Live

Guangzhou Baiyunshan Unit Secures Australian TGA Recertification, Reinforcing Global Quality Standards

Baiyunshan Pharmaceutical Subsidiary Gets China Supplementary Drug Nod for Brain Injury Injection

MT Newswires Live

BAIYUNSHAN PH Secures Regulatory Approval for Citicoline Sodium Injection New Dosage Strengths

China Traditional Chinese Medicine Holdings Schedules Board Meeting to Review Interim Results

Baiyunshan Pharmaceutical's Unit Gets Macao Drug Regulator's Nod for Cefazolin Sodium for Injection

MT Newswires Live

Luye Pharma Schedules Board Meeting to Review Interim Results, Weigh Dividend

BAIYUNSHAN PH Subsidiary Secures Pharmaceutical Registration Certificate from Macau Health Regulator

China Shineway Pharma Schedules Board Meeting on Interim Results, Dividend Decision

Shandong Boan Biotech Completes China Phase Ia Trial of Ba1302 CD228-Targeted ADC

Shandong Boan Biotech Schedules Board Meeting on Interim Results, Dividend Review

Zhongzhi Pharmaceutical Schedules Board Meeting to Review Interim Results, Dividend Plan

Tong Ren Tang Technologies Schedules Board Meeting on Interim Results, Dividend Decision

Baiyunshan Launches Sugar-Free Gold Edition Banlangen Granules

Modern Chinese Medicine Group Sets Board Meeting to Review Interim Results, Dividend Recommendation

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK1606/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","market":"HK","secType":"PLATE","nameCN":"Traditional Chinese Medicine","latestPrice":670.4988,"timestamp":1787299686774,"preClose":671.31415,"halted":0,"volume":100475800,"delay":0,"changeRate":-0.001215,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-0.815369,"latestTime":"08-21 16:00:00","open":674.6966,"high":682.66626,"low":665.86725,"amount":241048539,"amplitude":0.025024,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"pbRate":0.697796,"peRate":11.634893,"turnoverRate":0.006499,"increases":5,"decrements":5,"flats":1,"marketCap":70732525824,"floatMarketCap":47384181376},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1606\",,,,,undefined,":{"symbol":"BK1606","high":682.66626,"amplitude":0.025024,"preClose":671.31415,"low":665.86725,"pbRate":"0.697796","latestPrice":670.4988,"volume":100475800,"delay":0,"open":674.6966,"prevYearClose":830.6915,"prevWeekClose":666.386,"prevMonthClose":681.608,"prevQuarterClose":629.733,"fiveDayClose":666.386,"twentyDayClose":668.944,"sixtyDayClose":731.72,"secType":"PLATE","market":"HK","turnoverRate":0.006499,"peRate":11.634893,"marketCap":70732525824,"floatMarketCap":47384181376,"timestamp":1787299686774,"nameCN":"Traditional Chinese Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1606\",,,,undefined,":{"bkCode":"BK1606","up":5,"down":5,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1606\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1149843220","title":"BAIYUNSHAN PH Reports Interim Results with Net Profit Attributable to Shareholders of Approximately RMB 2.096 Billion, Down 16.7% Year-on-Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1149843220","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149843220?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:50","pubTimestamp":1787320219,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) has announced its interim results for 2026, with revenue reaching approximately RMB 42.091 billion, a modest increase of 0.61% year-on-year. Net profit attributable to...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","600332","BK1197","BK0070","BK0012","BK1515","BK1606","BK0096","BK1191","BK0188","BK0183","BK0097","BK1521","BK0028","BK0239","BK0175","00874"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162352221","title":"Modern Chinese Medicine Group Flags Expected Interim Loss of Approximately RMB 25.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1162352221","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162352221?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:48","pubTimestamp":1787316495,"startTime":"0","endTime":"0","summary":"Modern Chinese Medicine Group (01643) has issued a profit warning, indicating that it expects to record a net loss of approximately RMB 25.9 million for the six months ending June 30, 2026.This...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","01643"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260445","title":"Modern Chinese Medicine Expects RMB 25.9 Million H1 Net Loss vs RMB 2.5 Million Profit a Year Earlier","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260445","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260445?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:06","pubTimestamp":1787314009,"startTime":"0","endTime":"0","summary":"Modern Chinese Medicine expects RMB 25.9 million H1 net loss vs RMB 2.5 million profit a year earlierModern Chinese Medicine Group expects a net loss of about RMB 25.9 million for the six months ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4Wyl5n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01643","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661412260","title":"Modern Chinese Medicine Group Co - Expects Net Loss of Rmb25.9 Mln for Six Months Ended June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661412260","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661412260?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:06","pubTimestamp":1787314004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0F8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","01643","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260441","title":"Modern Chinese Medicine Group Co - Hy Net Loss Mainly Due to Increased Promotion, Marketing, Research and Development Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260441","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260441?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:06","pubTimestamp":1787314004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0F8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01643","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661804252","title":"Luye Pharma's Vaccine for Cervical Precancerous Lesions to Enter Phase II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2661804252","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661804252?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:36","pubTimestamp":1787290567,"startTime":"0","endTime":"0","summary":"Luye Pharma Group  said its LY01620 therapeutic mRNA vaccine for cervical precancerous lesions is set to enter a Phase II clinical trial in China.The trial will assess the candidate's safety and efficacy in patients with HPV16-positive high-grade cervical lesions, according to a Thursday Hong Kong exchange filing. Positive results from a Phase I study supported the move into Phase II, the company said in the filing.Shares of the company rose nearly 2% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02186","BK1583","BK1191","BK1606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194963178","title":"Guangzhou Baiyunshan Unit Secures Australian TGA Recertification, Reinforcing Global Quality Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=1194963178","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194963178?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:14","pubTimestamp":1787231674,"startTime":"0","endTime":"0","summary":"Guangzhou Pharmaceutical Holdings' Baiyunshan Zhongyi Pharmaceutical has officially received the TGA certificate from the Therapeutic Goods Administration of Australia, successfully passing the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0097","BK0188","BK0070","BK0028","BK1521","600332","00874","BK0196","BK1197","BK1515","BK0239","BK0175","BK1191","BK0096","BK0012","BK1606","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660400749","title":"Baiyunshan Pharmaceutical Subsidiary Gets China Supplementary Drug Nod for Brain Injury Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2660400749","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660400749?lang=en_us&edition=fundamental","pubTime":"2026-08-20 17:38","pubTimestamp":1787218718,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical  subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical received supplementary drug application approval from China's National Medical Products Administration for its cytidine diphosphate choline sodium injection.The drug, also known as citicoline sodium, is indicated for acute traumatic brain injury and post-brain surgery-related conditions, according to a Thursday filing with the Shanghai bourse.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0096","BK1197","00874","BK0012","600332","BK0183","BK1521","BK0196","BK0188","BK0097","BK1515","BK1606","BK1191","BK0239","BK0028","BK0070","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197235257","title":"BAIYUNSHAN PH Secures Regulatory Approval for Citicoline Sodium Injection New Dosage Strengths","url":"https://stock-news.laohu8.com/highlight/detail?id=1197235257","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197235257?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:36","pubTimestamp":1787128594,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) has announced that its majority-owned subsidiary, Guangzhou Baiyunshan Tiansin Pharmaceutical Co., Ltd., recently received the Drug Supplement Application Approval Notice from...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","01477","BK0070","BK1606","BK1515","00874","BK0012","BK1574","600332","BK0196","BK0239","BK1197","BK0183","BK0188","BK0175","BK0096","BK1191","BK0097","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660646315","title":"China Traditional Chinese Medicine Holdings Schedules Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660646315","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660646315?lang=en_us&edition=fundamental","pubTime":"2026-08-18 17:00","pubTimestamp":1787043607,"startTime":"0","endTime":"0","summary":"China Traditional Chinese Medicine Holdings schedules board meeting to review interim resultsChina Traditional Chinese Medicine Holdings will hold a board meeting on Aug. 28, 2026 to review interim re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL819K4v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1515","BK1606","00570"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660845460","title":"Baiyunshan Pharmaceutical's Unit Gets Macao Drug Regulator's Nod for Cefazolin Sodium for Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2660845460","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660845460?lang=en_us&edition=fundamental","pubTime":"2026-08-18 13:34","pubTimestamp":1787031298,"startTime":"0","endTime":"0","summary":"Guangzhou Baiyunshan Pharmaceutical's  unit, Guangzhou Baiyunshan Tianxin Pharmaceutical, received drug registration certificates from Macao's pharmaceutical regulator for cefazolin sodium for injection, according to a Shanghai bourse filing on Tuesday.The drug is used to treat infections in the respiratory tract, urinary tract, skin and soft tissues, bones and other parts of the body.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0183","BK0097","BK0028","00874","BK1606","BK0175","BK1191","BK1521","BK1197","BK0012","BK0188","BK0239","600332","BK0096","BK1515","BK0196","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660433500","title":"Luye Pharma Schedules Board Meeting to Review Interim Results, Weigh Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2660433500","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660433500?lang=en_us&edition=fundamental","pubTime":"2026-08-17 22:00","pubTimestamp":1786975234,"startTime":"0","endTime":"0","summary":"Luye Pharma schedules board meeting to review interim results, weigh dividendBoard meeting set for Aug. 29, 2026 to review interim results for the six months ended June 30, 2026.Directors will also co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL9QkJLD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1583","BK1191","02186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165773378","title":"BAIYUNSHAN PH Subsidiary Secures Pharmaceutical Registration Certificate from Macau Health Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1165773378","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165773378?lang=en_us&edition=fundamental","pubTime":"2026-08-17 17:50","pubTimestamp":1786960219,"startTime":"0","endTime":"0","summary":"BAIYUNSHAN PH (00874) has announced a key regulatory milestone for its controlled subsidiary. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited confirmed that its subsidiary, Guangzhou...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0175","BK1574","BK0070","BK1191","BK0183","BK0196","BK0096","BK1606","BK0028","BK0012","600332","BK1515","BK0097","BK1521","01477","00874","BK1197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660483186","title":"China Shineway Pharma Schedules Board Meeting on Interim Results, Dividend Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2660483186","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660483186?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:32","pubTimestamp":1786955541,"startTime":"0","endTime":"0","summary":"China Shineway Pharma schedules board meeting on interim results, dividend decisionChina Shineway Pharmaceutical will hold a board meeting on Aug. 27, 2026 to review interim results for the six months","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLGcVRW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","02877"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147506","title":"Shandong Boan Biotech Completes China Phase Ia Trial of Ba1302 CD228-Targeted ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147506","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659147506?lang=en_us&edition=fundamental","pubTime":"2026-08-14 22:17","pubTimestamp":1786717020,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotech completes China Phase Ia trial of BA1302 CD228-targeted ADCShandong Boan Biotechnology completed China Phase Ia dose-escalation for BA1302, a CD228-targeted antibody-drug conjuga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDLbBDZgq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1583","02186","BK1191","06955","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659475541","title":"Shandong Boan Biotech Schedules Board Meeting on Interim Results, Dividend Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2659475541","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659475541?lang=en_us&edition=fundamental","pubTime":"2026-08-14 22:15","pubTimestamp":1786716936,"startTime":"0","endTime":"0","summary":"Shandong Boan Biotech schedules board meeting on interim results, dividend reviewShandong Boan Biotechnology will hold a board meeting on Aug. 27, 2026.Agenda includes reviewing interim results for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL3K8zFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1161","02186","BK1606","BK1191","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659114104","title":"Zhongzhi Pharmaceutical Schedules Board Meeting to Review Interim Results, Dividend Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2659114104","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659114104?lang=en_us&edition=fundamental","pubTime":"2026-08-14 16:48","pubTimestamp":1786697302,"startTime":"0","endTime":"0","summary":"Zhongzhi Pharmaceutical schedules board meeting to review interim results, dividend planZhongzhi Pharmaceutical Holdings will hold a board meeting on Aug. 26, 2026.Directors will review unaudited inte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL1gccrb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1606","03737"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162114","title":"Tong Ren Tang Technologies Schedules Board Meeting on Interim Results, Dividend Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162114","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162114?lang=en_us&edition=fundamental","pubTime":"2026-08-14 16:45","pubTimestamp":1786697127,"startTime":"0","endTime":"0","summary":"Tong Ren Tang Technologies schedules board meeting on interim results, dividend decisionTong Ren Tang Technologies set a board meeting for Aug. 28, 2026 to review interim results for the six months en","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL1KzFsW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","LU1688375341.USD","BK0183","BK0239","BK0012","BK0086","BK0113","BK0196","BK1583","BK0188","BK1606","BK0028","BK1515","BK0097","01666","600085"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102855134","title":"Baiyunshan Launches Sugar-Free Gold Edition Banlangen Granules","url":"https://stock-news.laohu8.com/highlight/detail?id=1102855134","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102855134?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:40","pubTimestamp":1786628455,"startTime":"0","endTime":"0","summary":"At the recent West China Pharmaceutical Expo (西普会) in Boao, Hainan, a major event for China's health industry, Baiyunshan and Hutchison Whampoa (Guangzhou Baiyunshan Pharmaceutical Holdings Company...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0097","BK1521","BK0188","BK0070","BK0096","BK0239","BK1515","600332","BK1606","BK0012","BK1197","IPOS","BK0175","BK1191","BK0196","BK0028","00874","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659155284","title":"Modern Chinese Medicine Group Sets Board Meeting to Review Interim Results, Dividend Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2659155284","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659155284?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:56","pubTimestamp":1786618587,"startTime":"0","endTime":"0","summary":"Modern Chinese Medicine Group sets board meeting to review interim results, dividend recommendationModern Chinese Medicine Group will hold a board meeting on Aug. 28, 2026 to review interim results fo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL9h5s0x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01643","BK1606","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}